promo_leaderboard Ad
‹ All stocks
VKTX

Viking Therapeutics

VKTX · NASDAQ · Healthcare
$27.10
▲ $0.30 (1.13%)
$26.73 $27.56 $28.39 $29.22 $27.10 Nov 10 Nov 14 Nov 17
Day range
$26.76 – $27.42
Year range
$23.82 – $43.10
Open
$26.82
Previous close
$26.80
Market cap
$3.46B
Volume (24h)
$309.7K
Volume (52w)
$8.39M
Performance
7D
▼ -5.43%
1M
▲ 8.20%
3M
▼ -24.67%
6M
▼ -11.66%
1Y
▼ -29.08%
YTD
▼ -23.48%
3Y
▲ 130.28%
5Y
▲ 373.02%
All-time
▲ 238.80%
Key statistics
P/E ratio
-5.02
EPS (TTM)
$-5.40
Dividend yield
—
Dividend (TTM)
—
Payout ratio
—
Shares outstanding
127.5M
About Viking Therapeutics

Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.

Visit website
Country: United States of America
More in Healthcare